ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts
Argus has raised its target price for ACADIA Pharmaceuticals Inc. (ACAD) to $31.00, up from its previous rating. The biopharmaceutical company focuses on developing and commercializing medicines for central nervous system (CNS) disorders and rare diseases. This report, published on August 12, 2026, highlights …